LncRNA SNHG14 Facilitates Cisplatin Resistance Through Upregulating Notch2 via Binding to U2AF2 in Nasopharyngeal Carcinoma

ABSTRACT Background Cisplatin (DDP) is one of the commonly used chemotherapeutic drugs for nasopharyngeal carcinoma (NPC) patients, and the resistance of tumor cells to cisplatin is main obstacle for NPC treatment. This study explored effect and possible mechanism of lncRNA small nucleolar RNA host gene 14 ( SNHG14 ) on drug resistance of NPC cells to cisplatin. Methods Levels of SNHG14 and Notch2 in NPC tissues and cells were confirmed using RT‐qPCR. Western blot detected Notch2 and ABCB1 expression in NPC cells. IC50 of cisplatin‐treated NPC cells was tested utilizing 3‐(4,5‐dimethylthiazol‐2‐yl)‐2,5‐diphenyltetrazolium bromide (MTT). Cell proliferation and apoptosis were evaluated utilizing colony formation experiment and flow cytometry, respectively. RNA immunoprecipitation (RIP) assay was utilized to validate the target genes of U2AF2 . Notch2 mRNA stability was tested using actinomycin D. Results SNHG14 level was increased in both cisplatin‐resistant NPC tissues and cell lines. SNHG14 silencing in HNE1/DDP cells resulted in inhibition of chemoresistance to cisplatin. Conversely, upregulation of SNHG14 in HNE1 cells enhanced their resistance to cisplatin. SNHG14 exhibited an interaction with U2AF2 , leading to stabilization of Notch2 mRNA. Finally, Notch2 was involved in SNHG14 ‐mediated cisplatin resistance in NPC cells. Conclusion Our findings demonstrate SNHG14 plays a significant role in promoting chemoresistance of NPC cells to cisplatin through U2AF2 / Notch2 axis. These results highlight potential therapeutic targets for NPC treatment.